Literature DB >> 28089741

Inflammatory myopathy in a patient with Aicardi-Goutières syndrome.

Birutė Tumienė1, Norine Voisin2, Eglė Preikšaitienė3, Donatas Petroška4, Jurgita Grikinienė5, Rūta Samaitienė5, Algirdas Utkus3, Alexandre Reymond2, Vaidutis Kučinskas3.   

Abstract

Aicardi-Goutières syndrome (AGS) is an inflammatory disorder belonging to the recently characterized group of type I interferonopathies. The most consistently affected tissues in AGS are the central nervous system and skin, but various organ systems and tissues have been reported to be affected, pointing to the systemic nature of the disease. Here we describe a patient with AGS due to a homozygous p.Arg114His mutation in the TREX1 gene. The histologically proven inflammatory myopathy in our patient expands the range of clinical features of AGS. Histological signs of muscle biopsies in the proband, and in two other AGS patients described earlier, are similar to those seen in various autoimmune myositises and could be ascribed to inapproapriate IFN I activation. In view of signs of possible mitochondrial damage in AGS, we propose that mitochondrial DNA could be a trigger of autoimmune responses in AGS.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aicardi-Goutières syndrome; Autoimmune myositis; Exome sequencing; Inflammatory myopathy; Type I interferonopathy

Mesh:

Substances:

Year:  2017        PMID: 28089741     DOI: 10.1016/j.ejmg.2016.12.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes.

Authors:  Marco Luciani; Francesca Gatto; Monah Abou Alezz; Anna Maria Sole Giordano; Chiara Beghè; Lucrezia Della Volpe; Alessandro Migliara; Sara Valsoni; Marco Genua; Monika Dzieciatkowska; Giacomo Frati; Julie Tahraoui-Bories; Silvia Clara Giliani; Simona Orcesi; Elisa Fazzi; Renato Ostuni; Angelo D'Alessandro; Raffaella Di Micco; Ivan Merelli; Angelo Lombardo; Martin A M Reijns; Natalia Gromak; Angela Gritti; Anna Kajaste-Rudnitski
Journal:  J Exp Med       Date:  2022-03-09       Impact factor: 14.307

2.  The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

Authors:  Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky
Journal:  Ann Rheum Dis       Date:  2022-01-27       Impact factor: 27.973

3.  Toward an Inclusive, Congruent, and Precise Definition of Autoinflammatory Diseases.

Authors:  Per Wekell; Stefan Berg; Anna Karlsson; Anders Fasth
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

4.  De novo splice site variant of ARID1B associated with pathogenesis of Coffin-Siris syndrome.

Authors:  Laura Pranckėnienė; Evelina Siavrienė; Lucie Gueneau; Eglė Preikšaitienė; Violeta Mikštienė; Alexandre Reymond; Vaidutis Kučinskas
Journal:  Mol Genet Genomic Med       Date:  2019-10-19       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.